Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Some diseases were long considered incurable, even untreatable. Epidermolysis bullosa (EB) is one of them. But as technology advances, so does therapeutic possibilities. With the advent of gene therapy, ... Read more
A group of physicians and researchers in Germany and Italy were quietly making history in 2015, aware they were doing something extraordinary but refraining from going public. They needed ... Read more
Amicus Therapeutics’ Phase 3 trial of SD-101 cream to treat wounds in patients with epidermolysis bullosa did not meet the company’s primary and secondary treatment goals, Amicus announced. The ... Read more
In a recent update on its drug development program, Fibrocell Science addressed the therapy, FCX-007, it is developing for people with recessive dystrophic epidermolysis bullosa (RDEB). Results from the Phase ... Read more
Pin It on Pinterest